Novartis is experimenting with ways to use digital technology and specifically artificial intelligence to assist with the planning, monitoring, and distribution of medicine to patients as well – further strengthening the pharma supply change from manufacturing to the end user.
Pharma manufacturing is changing, of that there is little doubt. From the introduction of Industry 4.0 technology to new and more efficient processes and the rise of personalised medicines, there is no longer a one size fits all solution when it comes to making life-saving treatments.
The obvious challenge associated with personalised medicine lies in the manufacturing process - making smaller batches of medicine can be inconvenient, costly, and time-consuming. However, that may be set to change with the recent FDA approval of the world’s first prescription drug manufactured using 3D printing.
Reducing the time to market for medicine is a core goal of the pharmaceutical industry, and by playing its part in a new innovation centre GlaxoSmithKline (GSK) is helping develop the new technologies and processes to get remedies to the people who need them more efficiently than ever.
Industry 4.0 is changing the face of manufacturing in almost every corner of the globe. Here’s how the pharmaceutical industry can make the most of these exciting new opportunities.